Scholarlink

Background <p>Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Inflammation, marked by elevated high-sensitivity C-reactive protein (hs-CRP) levels, and dyslipidaemia, are critical contributors to atherosclerosis and cardiovascular risk. In Nigeria, where T2DM prevalence is rising, there is a need for more comprehensive risk prediction tools, incorporating both traditional and newer biomarkers such as hs-CRP. This study aimed to investigate the association between elevated hs-CRP levels and dyslipidaemia in Nigerian patients with T2DM and to explore the potential implications for cardiovascular risk prediction.</p> Methods <p>A hospital-based cross-sectional study was conducted among 150 T2DM patients and 150 age-matched controls. Data on socio-demographics, medical history, clinical characteristics, and laboratory parameters, including lipid profiles and hs-CRP levels, were collected. The relationship between hs-CRP levels and lipid parameters was assessed using Pearson’s correlation coefficient and independent t-tests.</p> Results <p>T2DM patients exhibited significantly higher hs-CRP levels (2.2 ± 1.8&#xa0;mg/L vs. 1.2 ± 1.0&#xa0;mg/L, <i>p</i> &lt; 0.001), dyslipidaemia (<i>p</i> &lt; 0.001), and blood pressure (SPB– 127.6 ± 12.4 mmHg, DBP– 77.6 ± 6.6 mmHg vs. SBP– 119.6 ± 10.8 mmHg, DBP– 72.1 ± 8.0 mmHg; <i>p</i> = 0.001) compared to controls. However, no significant correlation was found between hs-CRP levels and lipid parameters.</p> Conclusion <p>Although no direct association was found between elevated hs-CRP levels and dyslipidaemia, hs-CRP remains an important marker of cardiovascular risk possibly through non-lipid pathways, such as inflammation-driven endothelial dysfunction. Further research is needed to evaluate its potential role in refining cardiovascular risk assessment in the Nigerian T2DM population.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elevated high-sensitivity C-reactive protein and dyslipidaemia in type 2 diabetes mellitus: implications for cardiovascular risk prediction in Nigerian patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月17日

查看全文
  • Jamila Aminu Mohammed,
  • Bruno Basil,
  • Izuchukwu Nnachi Mba,
  • Nabilah Datti Abubakar,
  • Akeem Oyeyemi Lawal,
  • Jafaru Alunua Momoh,
  • Isah Adagiri Yahaya

摘要

Background

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). Inflammation, marked by elevated high-sensitivity C-reactive protein (hs-CRP) levels, and dyslipidaemia, are critical contributors to atherosclerosis and cardiovascular risk. In Nigeria, where T2DM prevalence is rising, there is a need for more comprehensive risk prediction tools, incorporating both traditional and newer biomarkers such as hs-CRP. This study aimed to investigate the association between elevated hs-CRP levels and dyslipidaemia in Nigerian patients with T2DM and to explore the potential implications for cardiovascular risk prediction.

Methods

A hospital-based cross-sectional study was conducted among 150 T2DM patients and 150 age-matched controls. Data on socio-demographics, medical history, clinical characteristics, and laboratory parameters, including lipid profiles and hs-CRP levels, were collected. The relationship between hs-CRP levels and lipid parameters was assessed using Pearson’s correlation coefficient and independent t-tests.

Results

T2DM patients exhibited significantly higher hs-CRP levels (2.2 ± 1.8 mg/L vs. 1.2 ± 1.0 mg/L, p < 0.001), dyslipidaemia (p < 0.001), and blood pressure (SPB– 127.6 ± 12.4 mmHg, DBP– 77.6 ± 6.6 mmHg vs. SBP– 119.6 ± 10.8 mmHg, DBP– 72.1 ± 8.0 mmHg; p = 0.001) compared to controls. However, no significant correlation was found between hs-CRP levels and lipid parameters.

Conclusion

Although no direct association was found between elevated hs-CRP levels and dyslipidaemia, hs-CRP remains an important marker of cardiovascular risk possibly through non-lipid pathways, such as inflammation-driven endothelial dysfunction. Further research is needed to evaluate its potential role in refining cardiovascular risk assessment in the Nigerian T2DM population.

Clinical trial number

Not applicable.